drugset / Trial / NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
Timeline
- Start
- 2025-11-27
- Primary completion
- 2028-11-15
- Completion
- 2028-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |